医保和商保创新药目录申报

Search documents
港股异动 | 药明巨诺-B(02126)午后涨超7% 首版商保创新药目录完成专家评审 5款CAR-T药物均过评
智通财经网· 2025-09-25 06:21
Core Viewpoint - WuXi AppTec's stock price increased by over 7% following the announcement that five CAR-T therapies, including its product Benodda, passed expert review for inclusion in the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory, indicating a positive regulatory signal for advanced therapies [1] Group 1: Company Performance - WuXi AppTec's stock price rose by 5.76% to HKD 4.22, with a trading volume of HKD 19.47 million [1] - The company is actively participating in the application process for the 2025 medical insurance and commercial insurance innovative drug directories [1] Group 2: Industry Insights - The approval of five CAR-T products, including WuXi AppTec's Benodda, reflects a commitment from regulators to enhance the accessibility of cutting-edge therapies [1] - CAR-T therapies have not yet entered the basic medical insurance directory due to their high costs, often exceeding one million yuan per treatment [1] - The current payment structure for CAR-T therapies is diverse, primarily relying on commercial health insurance, supplemented by special disease insurance, financial installment plans, and various assistance programs [1]